Discover

NTLA
Intellia Therapeutics, Inc.
17.24
2 x 12.78
2 x 21.65
bid
ask
+
0.32
1.89%
2 @ 07:15 AM
17.16 -0.08 (0.46%)
Ytd91.77%
1y60.67%
16.72
day range
17.83
7.95
52 week range
28.25
Open16.85Prev Close16.92Low16.72High17.83Mkt Cap2.41B
Vol3.72MAvg Vol6.54MEPS-3.52P/EN/AForward P/E-9.57
Beta1.81Short Ratio7.65Inst. Own76.84%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0650-d Avg14.05200-d Avg13.651yr Est26.63

NTLA News

Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
fool.com
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%

It might pull it off, provided several things fall right in place.

Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED)
benzinga.com
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED)

Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpar

Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
benzinga.com
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze

Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names whe

Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday
benzinga.com
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday

U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% a

benzinga.com
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outp

benzinga.com
Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target

Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral

Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
benzinga.com
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder

Intellia shares rise after new Phase 3 lonvo-z data showed significant reductions in HAE attacks and

benzinga.com
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA)

benzinga.com
Reported Saturday, Intellia Therapeutics' Lonvo-z Achieves 87% Attack Reduction And 62% Attack-Free

Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European A

benzinga.com
Intellia Therapeutics To Highlight Data From Global Phase 3 HAELO Clinical Trial Of Lonvo-Z In Hered

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolution

benzinga.com
Intellia Therapeutics Announces That Data From The Global Phase 3 HAELO Clinical Trial Of Lonvo-Z In

Intellia will also have a poster presentation detailing the burdens experienced by HAE patients livi

benzinga.com
Bernstein Maintains Market Perform on Intellia Therapeutics, Raises Price Target to $17

Bernstein analyst William Pickering maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market P

Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
benzinga.com
Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts updated their ratings on top companies. For full list of changes, including

benzinga.com
HC Wainwright & Co. Maintains Buy on Intellia Therapeutics, Lowers Price Target to $25

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Intellia Therapeutics (NASDAQ:NTLA)

benzinga.com
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $49

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy a

benzinga.com
Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target

Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral

benzinga.com
Intellia Therapeutics Q1 EPS $(0.81) Beats $(0.90) Estimate, Sales $15.048M Beat $14.793M Estimates

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.81) per share which beat the an

benzinga.com
Intellia Therapeutics Q1 EPS $(0.81) Beats $(0.90) Estimate, Sales $15.048M Beat $14.793M Estimate

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.81) per share which beat the an

Cathie Wood Trims Chip Exposure, Adds To AI Platforms—ETF Investors Watch Positioning
benzinga.com
Cathie Wood Trims Chip Exposure, Adds To AI Platforms—ETF Investors Watch Positioning

Cathie Wood trims chip exposure and adds AI platform and biotech bets, offering ETF investors insigh

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Robinhood Posts Downbeat Q1 Results, Joins Enphase Energy, Avis Budget And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
benzinga.com
Robinhood Posts Downbeat Q1 Results, Joins Enphase Energy, Avis Budget And Other Big Stocks Moving L

U.S. stock futures up, Nasdaq 100 gains 100 points. Robinhood shares fall 10.7% after reporting lowe

benzinga.com
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Raises Price Target to $58

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy a

benzinga.com
Goldman Sachs Maintains Sell on Intellia Therapeutics, Raises Price Target to $9

Goldman Sachs analyst Salveen Richter maintains Intellia Therapeutics (NASDAQ:NTLA) with a Sell a

benzinga.com
Citizens Maintains Market Outperform on Intellia Therapeutics, Raises Price Target to $30

Citizens analyst Silvan Turkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outpe

benzinga.com
Morgan Stanley Maintains Equal-Weight on Intellia Therapeutics, Raises Price Target to $15

Morgan Stanley analyst Terence Flynn maintains Intellia Therapeutics (NASDAQ:NTLA) with a Equal-W

Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the compan

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

This Target Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
benzinga.com
This Target Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday

Top analysts upgraded RPM, Dow, Intellia, Sempra, & Target stocks. See ratings & targets. Po

GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday
benzinga.com
GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday

Benzinga's top Wall Street analysts changed outlook on these names: AVAV cut to $290, OCUL raise

Earnings Scheduled For February 26, 2026
benzinga.com
Earnings Scheduled For February 26, 2026

10 Health Care Stocks With Whale Alerts In Today's Session
benzinga.com
10 Health Care Stocks With Whale Alerts In Today's Session

HCA Healthcare Posts Upbeat Q4 Earnings, Joins Redwire, General Motors And Other Big Stocks Moving Higher On Monday
benzinga.com
HCA Healthcare Posts Upbeat Q4 Earnings, Joins Redwire, General Motors And Other Big Stocks Moving H

10 Health Care Stocks With Whale Alerts In Today's Session
benzinga.com
10 Health Care Stocks With Whale Alerts In Today's Session

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks
benzinga.com
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 wil

10 Health Care Stocks Whale Activity In Today's Session
benzinga.com
10 Health Care Stocks Whale Activity In Today's Session

The Short List — Top 10 Most Shorted Stocks Right Now
benzinga.com
The Short List — Top 10 Most Shorted Stocks Right Now

Here's a look at the top ten most shorted stocks in the market right now, including Wendy's,

This Bath & Body Works Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
benzinga.com
This Bath & Body Works Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday

This SPS Commerce Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
benzinga.com
This SPS Commerce Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday

benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

Block Posts Downbeat Q3 Results, Joins Archer Aviation, DraftKings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
benzinga.com
Block Posts Downbeat Q3 Results, Joins Archer Aviation, DraftKings And Other Big Stocks Moving Lower

benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

Meta, eBay, Microsoft And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
benzinga.com
Meta, eBay, Microsoft And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday
benzinga.com
Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday

This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
benzinga.com
This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

Gold Falls 3%; Carter's Shares Gain After Q3 Earnings
benzinga.com
Gold Falls 3%; Carter's Shares Gain After Q3 Earnings

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles
benzinga.com
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a s